Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Czyz, J.
Right arrow Articles by Warzocha, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Czyz, J.
Right arrow Articles by Warzocha, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:1222-1230, 2004
© 2004 European Society for Medical Oncology

Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients

Background: The reported probability of survival of patients with Hodgkin's disease (HD) following high-dose chemotherapy with autologous stem cell transplantation (HDC/ASCT) is 35–65% at 5 years. The Polish Lymphoma Research Group investigated retrospectively prognostic factors for overall survival (OS) and event-free survival (EFS), and the risk of secondary malignancies in a large series of patients who underwent HDC/ASCT.

Patients and methods: The data of 341 consecutive patients treated in 10 centers from 1990 to 2002 were collected and analyzed.

Results: The actuarial 5-year OS and EFS were 64% [95% confidence interval (CI) 57% to 71%] and 45% (95% CI 39% to 51%), respectively. In the multivariate model, unfavorable prognostic factors for EFS were less than partial response at the time of ASCT [relative risk (RR), 2.92 (95% CI 1.68–5.08); P<0.001] and three or more previous chemotherapy lines (RR, 2.16; 95% CI 1.42–3.30; P<0.001). These two factors were also associated with unfavorable OS (RR, 3.32; 95% CI 1.90–5.79; P<0.001 and RR, 2.34, 95% CI 1.51–3.64; P<0.001). Five-year cumulative risk of secondary malignancy was 8.4% (95% CI 2% to 13%) and the only identified risk factor was splenectomy (P=0.02).

Conclusions: HDC/ASCT should be considered early in the course of disease for patients with a response after standard therapy.

J. Czyz*, R. Dziadziuszko, W. Knopinska-Postuszuy, A. Hellmann, L. Kachel, J. Holowiecki, J. Gozdzik, J. Hansz, A. Avigdor, A. Nagler, M. Osowiecki, J. Walewski, P. Mensah, W. Jurczak, A. Skotnicki, M. Sedzimirska, A. Lange, W. Sawicki, K. Sulek, M. Wach, A. Dmoszynska, A. Kus, T. Robak and K. Warzocha On behalf of the Polish Lymphoma Research Group

Medical University of Gdansk, Gdansk, Poland

* Correspondence to: Dr J. Czyz, Department of Haematology, Medical University of Gdansk, 80-211 Gdansk, Debinki St. 7, Poland. Tel: +48-58-349-22-30; Fax: +48-58-349-22-33; Email: jczyz{at}amgb.gda.pl

Key words: autologous transplantation, high-dose chemotherapy, Hodgkin's disease


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
B. Sirohi, D. Cunningham, R. Powles, F. Murphy, T. Arkenau, A. Norman, J. Oates, A. Wotherspoon, and A. Horwich
Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma
Ann. Onc., July 1, 2008; 19(7): 1312 - 1319.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Evens, J. Altman, B. Mittal, N Hou, A Rademaker, D Patton, L Kaminer, S Williams, S Duffey, D Variakojis, et al.
Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma
Ann. Onc., April 1, 2007; 18(4): 679 - 688.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.